Indication: Cutaneous Squamous Cell Carcinoma (cSCC)
A Randomized, Placebo-Controlled, Double-Blind Study Of Adjuvant Cemiplimab Versus Placebo After Surgery And Radiation Therapy In Patients With High Risk Cutaneous Squamous Cell Carcinoma
High Risk Patients
Sub-indication: High risk CSCC (after surgery and RT)
Line of Therapy: Adjuvant
Principal Investigator: Jae Jung, M.D.Norton Cancer Institute
Sponsor: Regeneron Pharmaceuticals, Inc.
Email for more information: Derm-NCIResearch@nortonhealthcare.org